Cellectar Biosciences, Inc. CLRB
1.22 USD -0.06 (-4.69%)
At closeNov 10, 2026, 4:00 PM EST
1.22 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
1.22 Day range 1.32
1.11 52-week range 4.70
- YTD
- -58.64%
- 1 year
- -65.54%
News
benzinga.com Cellectar Biosciences Q3 2026 Earnings Call Transcript Cellectar Biosciences (NASDAQ:CLRB) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
globenewswire.com Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström…
benzinga.com Cellectar Biosciences Q3 EPS $(0.46) Beats $(0.56) Estimate Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.56) by 17.86 percent. This is a 67.38 percent increase over losses…
benzinga.com Cellectar Biosciences To Present Three Posters For Its Radiopharmaceutical Candidate At American Society Of Hematology Annual Meeting Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters…
globenewswire.com Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3…
globenewswire.com Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for…
benzinga.com Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131 Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential…
globenewswire.com Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential…
globenewswire.com Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-market session. The company's market cap stands at $2.4 million. Option Care Health (NASDAQ:OPCH) stock…
globenewswire.com Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately…
benzinga.com Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to…
seekingalpha.com Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
seekingalpha.com Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
benzinga.com Cellectar Biosciences Q2 2026 Earnings Call Transcript On Thursday, Cellectar Biosciences (NASDAQ:CLRB) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by…
globenewswire.com Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program
benzinga.com Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.48) by 18.75 percent. This is a 83.19 percent increase over…
defenseworld.net Analysts Set Cellectar Biosciences, Inc. (NASDAQ:CLRB) PT at $11.00 Cellectar Biosciences, Inc. (NASDAQ: CLRB - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports.…
globenewswire.com Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for…- benzinga.com Cellectar Biosciences Announces Publication Of Results From Phase 1 Dose-Escalation Study Evaluating Iopofosine I 131 In Combination With Low-Dose Dexamethasone In 31 Patients With Heavily Pretreated R/R MM Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple MyelomaPublication Supports Continued Development of Iopofosine I 131 as a Novel…
globenewswire.com Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Cellectar Biosciences To Highlight Efficacy Results From Phase 2 CLOVER WaM Clinical Trial Of Iopofosine I 131 To Treat r/r WM At 2026 ASCO Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi TherapyPlans to Initiate Phase 3…
globenewswire.com Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3…- benzinga.com Cellectar Biosciences Files Prospectus For Offering Of Up To 51.2M Shares Of Common Stock By Selling Stockholders https://www.sec.gov/Archives/edgar/data/1279704/000110465926063918/tm2614975d1_s1.htm
- benzinga.com Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10 Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.
seekingalpha.com Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript- benzinga.com Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call
globenewswire.com Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com Cellectar Biosciences Q1 EPS $(1.33) Beats $(1.89) Estimate. Cash And Equivalents $8.35M Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.33) per share which beat the analyst consensus estimate of $(1.89) by 29.26 percent. This is a 69.07 percent increase over losses…
globenewswire.com Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for…
zacks.com Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
benzinga.com What's Going With Cellectar Biosciences Stock On Wednesday? Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after the stock closed almost 12% higher on Tuesday after positive clinical trial data and financing…
benzinga.com Crude Oil Down 4%; PayPal Shares Fall After Q1 Results US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2.1%, financials down 0.2%. PayPal shares fall 9%.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Dow Jumps Over 300 Points; Pfizer Posts Upbeat Earnings US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 earnings beat expectations. Asian markets close lower.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Market-Moving news for May 5th PINS: 19% | Pinterest shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates. CLRB: 145% | Cellectar Biosciences…- benzinga.com Earnings Scheduled For March 4, 2026
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Earnings Scheduled For August 14, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket